Receptor | Molecular structure | Expression | Sample type | Function |
---|---|---|---|---|
NKp 30 (NCR) | Immunoglobulin Superfamily | Resting and activated NK cells | stage IV melanoma patients | Activator [75] |
NKp 46 (NCR) | Immunoglobulin Superfamily | Resting and activated NK cells | stage IV melanoma patients | Activator [75] |
NKp 44(NCR) | Immunoglobulin Superfamily | Activated NK cells | 1106mel melanoma cell line | Activator [82] |
NKp 80 (NCR) | Immunoglobulin Superfamily | Resting and activated NK cells | melanoma metastasis patients | Activator [83] |
NKG2D | C-type lectins | NK, gamma delta T, CD8+ T cells | stage III–IV melanoma patients | Activator [1] |
DNAM-1(CD226) | Immunoglobulin Superfamily | All NK cells, T cells and monocytes | B16F10 melanoma cell line | Activator [84] |
KIR | Immunoglobulin Superfamily | NK, T cells | stage I–IV melanoma patients/ melanoma cell line | Inhibitor/ Activator [62] |
NKG2A/CD94 | C-type lectins | NK, Cytotoxic T-lymphocyte | B16F10 melanoma cell line | Inhibitor [85] |